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Abstract
Women have an increased risk of pulmonary hypertension (PH) but better survival com-
pared to men. Few studies have explored sex-based differences in population-based
cohorts with PH. We sought to determine whether sex was associated with hemodynamics
and survival in US veterans with PH (mean pulmonary artery pressure [mPAP] 25 mm
Hg) from the Veterans Affairs Clinical Assessment, Reporting, and Tracking database. The
relationship between sex and hemodynamics was assessed with multivariable linear mixed
modeling. Cox proportional hazards models were used to compare survival by sex for those
with PH and precapillary PH (mPAP 25 mm Hg, pulmonary artery wedge pressure
[PAWP] 15 mm Hg and pulmonary vascular resistance [PVR] > 3 Wood units) respec-
tively. The study population included 15,464 veterans with PH, 516 (3%) of whom were
women; 1,942 patients (13%) had precapillary PH, of whom 120 (6%) were women. Among
those with PH, women had higher PVR and pulmonary artery pulse pressure, and lower
right atrial pressure and PAWP (all p <0.001) compared with men. There were no significant
differences in hemodynamics according to sex in veterans with precapillary PH. Women
with PH had 18% greater survival compared to men with PH (adjusted HR 0.82, 95% CI
0.69–0.97, p = 0.020). Similarly, women with precapillary PH were 29% more likely to sur-
vive as compared to men with PH (adjusted HR 0.71, 95% CI 0.52–0.98, p = 0.040). In
PLOS ONE | https://doi.org/10.1371/journal.pone.0187734 November 9, 2017 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Ventetuolo CE, Hess E, Austin ED, Baro´n
AE, Klinger JR, Lahm T, et al. (2017) Sex-based
differences in veterans with pulmonary
hypertension: Results from the veterans affairs-
clinical assessment reporting and tracking
database. PLoS ONE 12(11): e0187734. https://doi.
org/10.1371/journal.pone.0187734
Editor: Aftab Ahmad, University of Alabama at
Birmingham, UNITED STATES
Received: June 24, 2017
Accepted: August 29, 2017
Published: November 9, 2017
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: Data in the Veterans
Affairs (VA)-Clinical Assessment Reporting and
Tracking Database are collected for clinical
purposes as part of the patient medical record and,
therefore, cannot be shared. They can be accessed
by any VA researcher through the Institutional
Review Board process. Interested researchers can
direct data access requests to: John C. Heldens,
CIP, CCRP, RAC Director of COMIRB University of
Colorado, Denver | Anschutz Medical Campus Mail
stop F490 13001 E. 17th Place, Room N3214
conclusion, female veterans with PH have better survival than males despite higher pulmo-
nary afterload.
Introduction
Pulmonary hypertension (PH) refers to an elevation in pulmonary artery pressures (PAP)
due to various etiologies. Precapillary PH is characterized by an increase in pulmonary vas-
cular resistance (PVR) which may be idiopathic, heritable, or associated with systemic dis-
eases (all referred to as World Health Organization [WHO] Group 1 pulmonary arterial
hypertension [PAH]) [1]. As many as 80% of prevalent WHO Group 1 patients are women
[2]. Precapillary PH also occurs in chronic lung disease and sleep disordered breathing
(WHO Group 3 PH), chronic thromboembolic disease (WHO Group 4 PH), or combined
with post-capillary PH in left heart disease (WHO Group 2 PH) [3]. PH is a frequent compli-
cation of highly prevalent cardiopulmonary diseases and is associated with increased mor-
bidity and mortality when present [4–9]. In the last two decades, disease burden for all types
of PH has increased, particularly among women [4]. Despite greater disease prevalence, it
appears that women with PH have improved survival compared to men with PH [5, 10–13],
but sex-based differences in outcomes have not been well-characterized outside of WHO
Group 1 PAH.
Hemodynamics are required for the diagnosis and treatment of PH (i.e., to detect increased
PVR and distinguish pre- from post-capillary PH) and are established predictors of survival
[14–17]. We have previously shown that in patient-level data from clinical trials men with
PAH had more severe hemodynamic abnormalities as compared to women with PAH [18].
Similarly, in the Registry to Evaluate Early and Long-term PAH Disease Management
(REVEAL) men with PAH had more hemodynamic derangement than women with PAH
[14]. Age appeared to modify the associations between sex and hemodynamics in our prior
study and sex and survival in REVEAL, with some discrepancies observed between the two
studies [14,18]. Since both were limited to patients with WHO Group 1 PAH, it is unknown
whether these observations extend to other quite common forms of PH. Large epidemiologic
cohorts with hemodynamic assessments in which to replicate these observations in a “real
world” unselected population of men and women with all forms of PH have to this point been
lacking.
Veterans are characterized by a particularly high prevalence of PH, and the presence of PH
is a strong predictor of increased mortality in this population [8]. We therefore sought to
determine whether sex is associated with hemodynamics and survival in a cohort of US veter-
ans who underwent right heart catheterization (RHC) in whom outcomes were tracked as part
of a national clinical quality initiative, the Veterans Affairs (VA) Clinical Assessment, Report-
ing, and Tracking (CART) program [19]. We hypothesized that in PH and precapillary PH,
women would have less severe hemodynamic impairment as compared to men. Second, we
hypothesized that women would have more favorable survival as compared to men with PH
and precapillary PH respectively. Finally, we explored whether survival differences (if present)
could be explained by hemodynamic differences and whether age modified any of the observed
relationships.
Sex differences in veterans with PH
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Methods
Study population
We evaluated all veterans with procedural data recorded in CART who underwent RHC as an
outpatient or inpatient in the VA system between October 1, 2007 and September 30, 2013. In
patients undergoing multiple RHCs, the first RHC was used to characterize hemodynamics
and values from this index procedure were included in the analysis. Further details about the
76 participating centers and RHC volume by center have previously been published [8,19].
Catheterization reports generated by the CART system pass rigorous quality control [20], in
concordance with the definitions and standards of the American College of Cardiology’s
National Cardiovascular Data Registry [21].
The source population included all subjects with RHC data available including values for
mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure (PAWP), cardiac
output (CO) measured by either assumed Fick and/or thermodilution methods, and height
and weight for calculation of body surface area. Variables were assessed for physiologic plausi-
bility and validated by two cardiologists with expertise in hemodynamic analysis and were
assigned a corrected value based on ancillary data (i.e., values that could be confirmed in the
medical record or could be calculated from other variables), or a value of missing where cor-
rect value(s) could not be identified, as previously described [8]. PVR was calculated as
(mPAP—PAWP)/CO and pulmonary artery pulse pressure (PAPP), a marker of RV loading
that predicts poor outcomes in various forms of PH [22,23], was calculated as systolic PAP—
diastolic PAP.
The final study population included those with PH (defined as a mPAP 25 mm Hg) and
those with precapillary PH (defined as a mPAP 25 mm Hg, a PAWP 15 mm Hg, and a
PVR> 3 Wood units) [24] stratified by sex.
Covariates
Clinical characteristics representing a comprehensive group of risk factors for the development
of PH [24–26] were captured via CART or from VA administrative data [8, 27–29]. Covariates
included age, sex, race (black, white, or other which included American Indian, Alaskan
Native, Asian, Native Hawaiian, or other Pacific Islander), body mass index (BMI) (catego-
rized as underweight, overweight, obese, and severely obese), history of systemic hypertension,
left heart failure (i.e., heart failure due to left ventricular systolic or diastolic dysfunction),
congestive heart failure (i.e., heart failure that may include RV or biventricular dysfunction),
diabetes mellitus, coronary artery disease (CAD) (considered present if history of myocardial
infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or pres-
ence of any obstructive disease on cardiac catheterization was present), chronic obstructive
pulmonary disease (COPD), human immunodeficiency virus (HIV), liver cirrhosis (viral and
non-viral hepatitis), chronic kidney disease (including patients receiving renal replacement
therapy), connective tissue disease, atrial fibrillation or flutter, interstitial lung disease, obstruc-
tive sleep apnea (OSA) and/or sleep disordered breathing, pulmonary embolism, any valvular
disease (regurgitation or stenosis), and tobacco use. Depression and posttraumatic stress disor-
der (PTSD) were also included as their prevalence varies by sex and they are associated with
cardiovascular outcomes and survival in US veterans and other populations [27, 28].
Outcomes
Our primary outcome of interest was survival. A minimum of one year of follow-up survival
data was available for all subjects. CART data was combined with longitudinal records
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captured in the VA electronic health record including survival and also linked to claims data
outside of the VA system. The Colorado Multiple Institutional Review Board approved this
study.
Statistical analysis
Continuous data were summarized as median (interquartile range [IQR]) and categorical
data was summarized as percentages (frequency) with Kruskal-Wallis or Chi-Square tests for
continuous or categorical comparisons respectively. The relationship between sex and hemo-
dynamic outcomes in the two cohorts with PH and precapillary PH was assessed with multi-
variable linear mixed modeling and expressed as least square means. Cox proportional
hazards models were used to examine the relationship between sex and survival in the PH
and precapillary PH cohorts. Kaplan Meier plots were constructed stratified by sex for both
groups.
All linear mixed models included a random intercept for hospital site and were adjusted for
multiple covariates of interest (detailed above) including: age, sex, race, BMI, history of sys-
temic hypertension, left heart failure and/or congestive heart failure, diabetes mellitus, CAD,
COPD, HIV, liver disease, chronic kidney disease/dialysis, connective tissue disease, atrial
fibrillation or flutter, interstitial lung disease, OSA and/or sleep disordered breathing, pulmo-
nary embolism, any valvular regurgitation or stenosis, tobacco use, cancer, depression, PTSD,
and inpatient status. Cox proportional hazards models included the same covariates for the
PH cohort. A low number of events for women in the precapillary PH group only allowed
simultaneous adjustment for a much smaller number of covariates (relative to the PH cohort).
Age, sex, race, BMI, and inpatient status were automatically included in Cox models for the
precapillary PH group. Potential confounding by the remaining covariates was assessed by
adding each individually to a model containing the five aforementioned covariates to assess
the impact each had on the effect estimate for sex. Chronic kidney disease/dialysis was
included in the final Cox models as it had the greatest impact (changing the parameter esti-
mate for sex by> 15%, whereas all others had a much smaller impact, with a change of typi-
cally a few percent in all cases).
Finally, exploratory analyses were conducted to determine whether 1) age modified the sex-
hemodynamic and sex-survival relationships and 2) whether a significant proportion of the
relationship between sex and survival was mediated (explained by) by the hemodynamic vari-
ables. We assessed for a sex by age interaction and included an interaction term (sexage) in
the multivariable models when there was evidence of effect modification (p< 0.05) to deter-
mine whether there was a change in effect estimates. Age was assessed as both a categorical
variable (age < 55, [55–65], and 65) and a continuous variable.
Modeling for the mediator analysis required that 1) multivariate linear mixed models con-
firmed that sex was an independent predictor of hemodynamics and 2) Cox proportional haz-
ards modeling demonstrated sex was a significant predictor of survival after adjustment for
multiple covariates. A test statistic for mediation was then created using the product method
[30,31], such that “a” was the coefficient of sex in a multivariate mixed model with the hemo-
dynamic mediator of interest as the outcome and “b” was the coefficient of the hemodynamic
mediator in the adjusted Cox model for survival:
Zstatistic ¼ numerator  denominator;
Sex differences in veterans with PH
PLOS ONE | https://doi.org/10.1371/journal.pone.0187734 November 9, 2017 4 / 15
where
Numerator ¼ ða standard errorof aÞ  ðb standard error of bÞ
Denominator ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
½a2  ðstandard errorof bÞ2 þ b2  ðstandarderrorof bÞ2 þ 1
q

The Z statistic was then compared to the percentiles of a standard normal distribution, and
mediation was considered significant if p< 0.05.
Each hemodynamic variable was treated as a separate hypothesis, and therefore modeled
independently in all models. Data preparation and analyses were conducted using SAS version
9.4 (SAS Institute, Cary North Carolina) and R version 3.3.1. Statistical significance was
defined as p<0.05.
Results
We identified 28,775 index RHC records available for analysis in which subjects had
mPAP 25 mm Hg. Of these, N = 15,464 (54%) had CO recorded (by Fick, thermodilution,
or both). The final dataset included 22 subjects (0.1%) who were assigned a corrected hemody-
namic measurement based on ancillary data (i.e., values that could be confirmed in the medical
record or could be calculated from other variables). The final study population included
15,464 subjects with PH, 516 (3%) of whom were women. There were 1,942 (13%) subjects
with precapillary PH, 120 (6%) of whom were women.
Characteristics of the two study cohorts are presented in Tables 1 and 2, respectively, by
sex. Among those with PH, women tended to be younger, black, more severely obese
(BMI 33.5 kg/m2) and were less likely to have systemic hypertension as compared to men
(Table 1). While these differences were highly statistically significant due to the large sample
size, the relative proportions were similar. As expected, men were much more likely to have a
diagnosis of left heart failure, CAD, atrial fibrillation and chronic kidney disease while women
were much more likely to have a diagnosis of depression. There were similar rates of pulmo-
nary comorbidities and PTSD, while men were more likely to have been inpatients during car-
diac catheterization and have cancer. In those with precapillary PH, these observations were
similar (Table 2). Women with precapillary PH were more likely to have a history of connec-
tive tissue disease than men with precapillary PH (13.3% vs. 4.4%, p< 0.001).
Unadjusted median (IQR) hemodynamic values by sex are presented in Table 3 for the
cohorts. There were moderate elevations in pulmonary pressures across all groups. Women
with PH had higher PVR and PAPP and lower PAWP and right atrial pressure (RAP)
(p< 0.001 for all) compared to men (Table 4). For example, women with PH tended to have
approximately a 1 mm Hg lower RAP (-0.9 mm difference, 95% confidence interval [CI] -1.4
to -0.4 mm Hg, p< 0.001) and a 2 mm Hg higher PAPP (1.9 mm Hg difference, 95% CI 0.9 to
2.8, p< 0.001) as compared to men with PH controlling for demographics, body size, medical
comorbidities, inpatient status, and site. In the cohort with precapillary PH, there were no sig-
nificant differences in hemodynamics although effect estimates and trends were similar
(higher PVR and PAPP, lower PAWP and RAP in women compared to men) in this smaller
sample. Despite higher levels of pulmonary afterload (PVR and PAPP) in women with preca-
pillary PH, there were no differences in RV diastolic pressures between men and women
(p = 0.78) with precapillary PH.
Women with PH had 18% increased survival compared to men with PH (hazard ratio [HR]
0.82, 95% CI 0.69–0.97, p = 0.020) after adjustment for multiple clinical variables and potential
confounders. Similarly, in the precapillary PH subgroup women had a 29% reduction in the
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risk of death as compared to men although precision was decreased for this comparison due to
a smaller sample size (HR 0.71, 95% CI 0.52–0.98, p = 0.040). Figs 1 and 2 demonstrate the
Kaplan-Meier survival curves for PH and precapillary PH respectively for up to 1750 days after
RHC.
After confirming that sex was significantly associated with both hemodynamics and
survival in the PH cohort, we sought to determine if hemodynamics explained a significant
proportion of the sex-survival relationship in those with PH. None of the hemodynamic
parameters met the threshold for mediation (data not shown; p> 0.05 for all). In our
Table 1. Characteristics of the total cohort with pulmonary hypertension*, by sex.
Variable All Women Men P value
Number 15464 516 14948
Age, years 65.2 (60.4,73.3) 59.3 (53.3,66.9) 65.3 (60.6,73.5) <0.001
Race, % (n) <0.001
White 73.3 (11333) 60.7 (313) 73.7 (11020)
Black 19.6 (3038) 31.6 (163) 19.2 (2875)
Other 7.1 (1093) 7.8 (40) 7.0 (1053)
Body mass index, % (n) <0.001
Normal (18.5–25 kg/m2) 17.6 (2725) 17.4 (90) 17.6 (2635)
Underweight (<18.5 kg/m2) 0.9 (133) 2.1 (11) 0.8 (122)
Overweight (25–30 kg/m2) 29.5 (4561) 23.6 (122) 29.7 (4439)
Obese (30–35 kg/m2) 24.7 (3814) 23.8 (123) 24.7 (3691)
Severely obese (35 kg/m2) 27.4 (4231) 32.9 (170) 27.2 (4061)
Systemic hypertension, % (n) 89.9 (13901) 82.9 (428) 90.1 (13473) <0.001
Diabetes mellitus, % (n) 52.6 (8131) 44.8 (231) 52.8 (7900) <0.001
Tobacco use, % (n) 59.3 (9171) 47.9 (247) 59.7 (8924) <0.001
Cardiac conditions
Congestive heart failure, % (n) 69.4 (10728) 56.2 (290) 69.8 (10438) <0.001
Left heart failure, % (n) 15.2 (2347) 9.1 (47) 15.4 (2300) <0.001
Coronary artery disease, % (n) 57.9 (8957) 30.4 (157) 58.9 (8800) <0.001
Valvular disease, % (n) 39.4 (6086) 37.6 (194) 39.4 (5892) 0.432
Atrial fibrillation or flutter, % (n) 33.3 (5145) 19.6 (101) 33.7 (5044) <0.001
Pulmonary conditions
COPD, % (n) 38.0 (5882) 32.9 (170) 38.2 (5712) 0.017
Obstructive sleep apnea, % (n) 13.3 (2062) 12.4 (64) 13.4 (1998) 0.571
Pulmonary embolism, % (n) 3.9 (602) 5.4 (28) 3.8 (574) 0.086
Systemic conditions
Chronic kidney disease, % (n) 35.2 (5442) 18.2 (94) 35.8 (5348) <0.001
HIV infection, % (n) 0.5 (79) 0.2 (1) 0.5 (78) 0.476
Liver cirrhosis, % (n) 7.4 (1139) 5.8 (30) 7.4 (1109) 0.198
Connective tissue disease, % (n) 3.0 (465) 10.3 (53) 2.8 (412) <0.001
Sickle cell anemia, % (n) 0.0 (6) 0.2 (1) 0.0 (5) 0.495
Posttraumatic stress disorder, % (n) 13.5 (2082) 13.2 (68) 13.5 (2014) 0.899
Depression, % (n) 27.9 (4311) 44.2 (228) 27.3 (4083) <0.001
Inpatient status, % (n) 52.1 (8063) 43.4 (224) 52.4 (7839) <0.001
Active cancer, % (n) 16.2 (2504) 11.4 (59) 16.4 (2445) 0.003
*Defined as a mean pulmonary artery pressure 25 mm Hg. Data are shown as % (n) or median (interquartile range). COPD = chronic obstructive
pulmonary disease; HIV = human immunodeficiency virus
https://doi.org/10.1371/journal.pone.0187734.t001
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exploratory analyses age did not modify the associations seen between sex and hemodynamics
or sex and survival (data not shown).
Discussion
In a large cohort of US veterans with PH women have different hemodynamic profiles and
improved survival compared to men. Hemodynamics in women were characterized by a more
compensatory RV response (lower RAP) despite increased afterload (higher PVR, higher
PAPP) as compared to men; assessment for age-related interactions did not influence these
Table 2. Characteristics of the subgroup with precapillary pulmonary hypertension†, by sex.
Variable All Women Men P value
Number 1942 120 1822
Age, years 65.7 (60.5,74.3) 57.6 (52.3,67.3) 66.1 (61.1,74.6) <0.001
Race, % (n) <0.001
White 68.3 (1319) 51.7 (62) 69.8 (1271)
Black 24.1 (466) 38.3 (46) 23.1 (420)
Other 7.5 (145) 10.0 (12) 7.2 (131)
Body mass index, % (n) 0.399
Normal (18.5–25 kg/m2) 28.4 (551) 24.2 (29) 28.6 (522)
Underweight (<18.5 kg/m2) 2.1 (41) 1.7 (2) 2.1 (39)
Overweight (25–30 kg/m2) 32.5 (632) 30.8 (37) 32.7 (595)
Obese (30–35 kg/m2) 21.0 (408) 21.7 (26) 21.0 (382)
Severely obese (35 kg/m2) 16.0 (310) 21.7 (26) 15.6 (284)
Systemic hypertension, % (n) 86.3 (1675) 85.8 (103) 86.3 (1572) 0.753
Diabetes mellitus, % (n) 44.8 (870) 42.5 (51) 45.0 (819) 0.424
Tobacco use, % (n) 64.4 (1251) 48.3 (58) 65.5 (1193) <0.001
Cardiac conditions
Congestive heart failure, % (n) 59.5 (1156) 45.0 (54) 60.5 (1102) 0.001
Left heart failure, % (n) 12.1 (235) 1.7 (2) 12.8 (233) 0.001
Coronary artery disease, % (n) 49.6 (963) 26.7 (32) 51.1 (931) <0.001
Valvular disease, % (n) 27.0 (525) 19.2 (23) 27.6 (502) 0.058
Atrial fibrillation or flutter, % (n) 24.7 (479) 9.2 (11) 25.7 (468) <0.001
Pulmonary conditions
COPD, % (n) 54.4 (1057) 45.0 (54) 55.0 (1003) 0.041
Obstructive sleep apnea, % (n) 11.2 (218) 10.0 (12) 11.3 (206) 0.772
Pulmonary embolism, % (n) 4.8 (93) 4.2 (5) 4.8 (88) 0.913
Systemic conditions
Chronic kidney disease, % (n) 29.4 (571) 14.2 (17) 30.4 (554) <0.001
HIV infection, % (n) 0.7 (14) 0.8 (1) 0.7 (13) 1.000
Liver cirrhosis, % (n) 9.7 (188) 5.8 (7) 9.9 (181) 0.189
Connective tissue disease, % (n) 4.9 (96) 13.3 (16) 4.4 (80) <0.001
Sickle cell anemia, % (n) 0.2 (3) 0.8 (1) 0.1 (2) 0.453
Posttraumatic stress disorder, % (n) 12.1 (235) 14.2 (17) 12.0 (218) 0.567
Depression, % (n) 26.1 (506) 46.7 (56) 24.7 (450) <0.001
Inpatient status, % (n) 43.0 (835) 29.2 (35) 43.9 (800) 0.002
Active cancer, % (n) 16.4 (319) 9.2 (11) 16.9 (308) 0.037
†Defined as a mean pulmonary artery pressure 25 mm Hg, a pulmonary capillary wedge pressure 15 mm Hg, and a pulmonary vascular resistance > 3
Wood units. Data are shown as % (n) or median (interquartile range). COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus
https://doi.org/10.1371/journal.pone.0187734.t002
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results. Sex-based hemodynamic and survival differences persisted after adjustment for multi-
ple comorbid conditions and potential confounders. In veterans with precapillary PH, survival
differences persisted and hemodynamic patterns were similar, although not statistically signifi-
cant. The difference in survival between women and men with PH was not mediated by the
Table 3. Unadjusted hemodynamic variables for pulmonary hypertension cohort and precapillary pulmonary hypertension subgroup, by sex.
Pulmonary hypertension* Precapillary pulmonary hypertension†
Variable N
missing
All Women Men P value N
missing
All Women Men P
value
15464 516 14948 1942 120 1822
RAP, mm Hg 143 12.0
(8.0,15.0)
10.0
(7.0,14.0)
12.0
(8.0,15.0)
<0.001 10 8.0 (5.0, 10.0) 8.0 (5.0, 10.0) 8.0 (5.0, 10.0) 0.908
mPAP, mm
Hg
0 34.0
(29.0,41.0)
33.0
(28.8,40.0)
34.0
(29.0,41.0)
0.731 0 32.0 (28.0,
40.0)
32.0 (28.0,
41.0)
32.0 (28.0,
40.0)
0.907
PAWP, mm
Hg
0 21.0
(16.0,26.0)
19.0
(14.0,25.0)
21.0
(16.0,26.0)
<0.001 0 12.0
(9.0,14.0)
11.0
(9.0,14.0)
12.0
(9.0,14.0)
0.555
CI, L/min/m2 0 2.3 (1.9,2.8) 2.4 (2.0,2.9) 2.3 (1.9,2.8) 0.005 0 2.2 (1.9,2.6) 2.4 (2.0,2.8) 2.2 (1.9,2.6) 0.008
PVR, Wood
units
46 2.5 (1.7,3.8) 3.1 (2.0,4.6) 2.5 (1.7,3.7) <0.001 0 4.6 (3.6,6.5) 4.9 (3.8,7.0) 4.5 (3.6,6.5) 0.189
PAPP, mm
Hg
34 28.0
(21.0,35.0)
27.0
(22.0,35.8)
28.0
(21.0,35.0)
0.448 8 31.0
(24.0,40.0)
31.0
(23.0,43.0)
31.0
(24.0,40.0)
0.575
* Defined as a mean pulmonary artery pressure (mPAP) 25 mm Hg;
†Defined as a mPAP 25 mm Hg, a pulmonary artery wedge pressure (PAWP) 15 mm Hg, and a pulmonary vascular resistance (PVR) > 3 Wood units;
RAP = right atrial pressure; CI = cardiac index; PAPP = pulmonary artery pulse pressure.
https://doi.org/10.1371/journal.pone.0187734.t003
Table 4. Associations between sex and hemodynamics in pulmonary hypertension* cohort and precapillary pulmonary hypertension subgroup
after multivariable adjustment‡.
Pulmonary hypertension* Precapillary pulmonary hypertension†
Variable Women Men Difference, women vs.
men
P value Women Men Difference, women vs.
men
P value
RAP, mm Hg 12.3
(11.6,12.9)
13.2
(12.7,13.7)
-0.9 (-1.4,-0.4) <0.001 8.1 (7.0,9.2) 8.2 (7.4,9.0) -0.2 (-1.0,0.7) 0.710
mPAP, mm Hg 36.3
(35.4,37.3)
36.0
(35.3,36.7)
0.4 (-0.4,1.1) 0.352 35.9
(33.7,38.0)
36.7
(35.1,38.3)
-0.8 (-2.5,0.8) 0.318
PAWP, mm
Hg
19.1
(18.3,20.0)
20.6
(20.0,21.3)
-1.5 (-2.1,-0.9) <0.0001 10.8
(10.1,11.6)
10.5
(9.9,11.1)
0.3 (-0.3,0.9) 0.278
CI, L/min/m2 2.6 (2.5,2.7) 2.6 (2.5,2.6) 0.0 (0.0,0.1) 0.132 2.5 (2.3,2.6) 2.4 (2.3,2.5) 0.1 (0.0,0.2) 0.154
PVR, Wood
units
4.2 (4.0,4.5) 3.4 (3.2,3.6) 0.8 (0.6,1.0) <0.0001 6.1 (5.4,6.8) 5.8 (5.3,6.3) 0.3 (-0.3,0.8) 0.283
PAPP, mm Hg 32.0
(30.7,33.2)
30.1
(29.2,31.0)
1.9 (0.9,2.8) 0.0001 37.2
(34.1,40.3)
36.7
(34.5,39.0)
0.5 (-1.9,2.9) 0.700
Data are presented as least square means estimates (95% confidence interval).
* Defined as a mean pulmonary artery pressure (mPAP) 25 mm Hg;
†Defined as a mPAP 25 mm Hg, a pulmonary artery wedge pressure (PAWP) 15 mm Hg, and a pulmonary vascular resistance (PVR) > 3 Wood units;
RAP = right atrial pressure; CI = cardiac index; PAPP = pulmonary artery pulse pressure.
‡ Models included a random intercept for hospital site and were adjusted for age, sex, race, body mass index, systemic hypertension, left heart failure and/or
congestive heart failure, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease, human immunodeficiency virus infection, liver
disease, chronic kidney disease, connective tissue disease, atrial fibrillation or flutter, interstitial lung disease, obstructive sleep apnea and/or sleep
disordered breathing, pulmonary embolism, any valvular disease, tobacco use, cancer, depression, posttraumatic stress disorder, and inpatient status.
https://doi.org/10.1371/journal.pone.0187734.t004
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hemodynamic differences observed by sex. These results suggest distinct sex-based phenotypes
in an unselected, population-based cohort of veterans with elevated pulmonary pressures.
Female sex is a well-known risk factor for WHO Group 1 PAH, but recent epidemiologic
data suggests that men with PAH have poorer survival than women with PAH [4, 11, 12]. Hor-
monal regulation of cardiopulmonary function, sex-based differences in response to PAH
therapy [32, 33], or differences in RV adaptation have been proposed as possible explanations
for these observations. RV function has been identified as a major determinant of outcome in
PAH, but also in PH due to left heart disease [5–7]. Heart failure with preserved ejection frac-
tion (HFpEF) is more common in women [34, 35], yet women are less likely to develop RV
dysfunction than men with HFpEF [13]. In idiopathic PAH, women have greater improve-
ments in RV function with PAH therapy despite similar reductions in PVR as compared to
men, and sex-based differences in the RV response explain a significant portion of the survival
benefit seen in women as compared to men [36]. Women demonstrated lower RAP as com-
pared to men in our study. Elevated RAP occurs in RV failure and has been consistently
Fig 1. Kaplan-Meier curve for cohort of subjects with pulmonary hypertension (PH) by sex. Dotted line is
women, solid line is men.
https://doi.org/10.1371/journal.pone.0187734.g001
Sex differences in veterans with PH
PLOS ONE | https://doi.org/10.1371/journal.pone.0187734 November 9, 2017 9 / 15
associated with poor survival in pulmonary vascular disease [15,16]. The associations demon-
strated here are akin to earlier observations from “pure” WHO Group 1 PAH patients as well
as patients with HFpEF and presumed pulmonary venous (or postcapillary) PH, suggesting
persistent sex-based phenotypes across all types of pulmonary vascular disease.
The principal determinant of RV afterload is classically thought of as PVR, but more
recently stiffening of large pulmonary arteries has also been shown to be important. Our find-
ings that survival in women with PH was increased compared to men with PH despite higher
PVR and higher PAPP (a measurement of RV loading) suggests that sex-specific RV adapta-
tion patterns may exist and account for differences in survival. These data provide a clinical
correlate to converging lines of experimental data showing a favorable effect by estrogen on
pulmonary artery-RV coupling in PH in vivo [37–39]. In the systemic circulation, female sex
and sex hormones have been proposed to contribute to vascular-ventricular coupling as well
[40,41]. Assessment of RV function was limited to central hemodynamic measurements in our
Fig 2. Kaplan-Meier curve for cohort of subjects with precapillary pulmonary hypertension (PH) by
sex. Dotted line is women, solid line is men.
https://doi.org/10.1371/journal.pone.0187734.g002
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study and hemodynamic differences did not mediate the survival differences observed, per-
haps due to sample or effect size limitations; more robust measures of RV morphology (e.g.,
echocardiography or cardiac magnetic resonance imaging) may have improved sensitivity to
detect such relationships.
While our observations are certainly not generalizable to WHO Group 1 PAH, our findings
may be more representative of a “real world” population of patients with PH. In fact, sub-
groups of classically idiopathic PAH, pre- and post-capillary PH patients may have similar
genetic features and hemodynamic derangements that contribute to poor outcomes in all
groups [3, 42]. These clinical phenotypes may represent a spectrum of pulmonary vascular
abnormalities with shared pathobiologic mechanisms. As in right heart failure, women with
left heart failure have a better prognosis, but this is not explained by the etiology of heart failure
or degree of left ventricular dysfunction [43–46] (interestingly PAWP was lower in women
than in men in our study). It is plausible that sex-based prevalence and outcome differences in
left heart failure are driven by differences in pulmonary hemodynamics and the right heart
and that sex and/or sex hormones may play an important role in PH regardless of how it is
classified clinically.
We failed to detect any significant interactions between sex and age for the outcomes of
hemodynamics or survival, which may be due to the low number of younger age subjects (par-
ticularly women) in this population. We have previously shown that in clinical trial partici-
pants with WHO Group 1 PAH, men had greater hemodynamic burden (including higher
RAP, as seen here, but also higher mPAP and PVR) as compared to women, but some of these
differences were attenuated after age 45 [18]. In REVEAL, men with PAH had higher RAP and
mPAP at diagnosis (as well as worse survival especially in those older than 60 years of age) as
compared to women with PAH [12–14]. These observations have not been consistent across
all WHO Group 1 PAH registries [47,48], however, and it is therefore not surprising that our
results from an unselected veteran population would be somewhat inconsistent with prior
reports. Given the average age of the study subjects, it is likely that almost all women included
were post-menopausal. Although we do not have confirmation of menopausal status, the
inclusion of pre-menopausal women in the study sample were this data available may have
provided additional insights.
There was a greater proportion of black women compared to men in both the PH and the
precapillary PH groups. Observational studies have shown a more exaggerated female predom-
inance among blacks as compared to whites with WHO Group 1 PAH [2,16]. Outcomes in
both right and left heart failure may be poorer in blacks, there are baseline differences in RV
structure in function that vary by race/ethnicity in health, and we have shown a strong rela-
tionship between echocardiographic PH and heart failure admissions among black partici-
pants from the Jackson Heart Study [9, 49–51]. It is somewhat surprising then that women
had improved survival compared to men given the baseline differences in race, although the
models for both hemodynamics and survival accounted for race in the PH and precapillary PH
groups.
Study limitations include those inherent to a retrospective cross-sectional study with data
derived from electronic records. Still, excellent quality control is maintained in the CART
database [20] and we undertook additional steps to ensure physiologic plausibility of all hemo-
dynamic values assessed. There was a very small amount of missing data and at least one year
of follow-up was required with confirmed survival status in the VA electronic health record
and via outside claims data. Our study population was middle-aged US veterans with multiple
medical comorbidities, roughly 50% of whom were inpatient during their right heart catheteri-
zations, making “pure” WHO Group classification difficult and increasing the likelihood of
confounding by indication and selection bias. Detailed data on medication use, including use
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of targeted PAH therapies, was not available. We adjusted for many factors and comorbid con-
ditions that varied by sex as well as inpatient status with persistence of our findings, but resid-
ual confounding could certainly still exist and explain our findings.
The cohorts were predominantly male (reflecting the population of all US veterans) and the
subset with precapillary PH was modest (n = 1930, with n = 120 women), limiting our power
to detect hemodynamic differences in this group. The hemodynamic differences observed
between men and women were small, raising the question of clinical relevance. We do not
have repeated hemodynamic measures over time or additional measures of RV function (e.g.,
echocardiography or magnetic resonance imaging), both of which would potentially lend
greater insight to our cross-sectional observations. CART does represent to our knowledge the
largest available database of hemodynamics worldwide with extensive complementary infor-
mation available on patient demographics, anthropometrics, and all comorbid conditions rele-
vant to the pulmonary circulation, however, and the sample size still dwarfs those available in
WHO Group 1 PAH (a rarer condition with much smaller cohorts of hemodynamic informa-
tion available).
In summary, our data demonstrate clinical, hemodynamic, and outcome differences by sex
among a general population of US veterans with elevated pulmonary pressures. Women have
improved survival compared to men with PH and precapillary PH despite higher PVR and
PAPP, which is perhaps explained by better RV adaptation. This work should generate addi-
tional hypotheses about unique sex-based phenotypes in all forms of pulmonary vascular
disease.
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